• 7423 Citations
  • 26 h-Index
20022019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Melanoma Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Ligands Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

Desmoplastic melanoma: a brief review and the efficacy of immunotherapy

Ochoa, C. E. & Joseph, R. W., Mar 4 2019, In : Expert Review of Anticancer Therapy. 19, 3, p. 205-207 3 p.

Research output: Contribution to journalEditorial

Renal Cell Carcinoma
Immunotherapy
Melanoma
nivolumab
1 Citation (Scopus)

Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment

Liu, F. X., Witt, E. A., Ebbinghaus, S., Dibonaventura Beyer, G., Basurto, E. & Joseph, R. W., Jan 1 2019, In : Cancer Nursing. 42, 1, p. E52-E59

Research output: Contribution to journalArticle

Melanoma
Nurses
Disease-Free Survival
Appointments and Schedules
Therapeutics
3 Citations (Scopus)

Association between programmed death-Ligand 1 expression and the vascular endothelial growth factor pathway in angiosarcoma

Bagaria, S. P., Gatalica, Z., Maney, T., Serie, D., Parasramka, M., Attia, S., Krishna, M. & Joseph, R. W., Mar 22 2018, In : Frontiers in Oncology. 8, MAR, 71.

Research output: Contribution to journalArticle

Hemangiosarcoma
Vascular Endothelial Growth Factor A
Ligands
Neoplasms
Gene Expression
15 Citations (Scopus)

Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Dronca, R. S., Hersey, P., Weber, J. S., Patnaik, A., De Alwis, D. P., Perrone, A., Zhang, J., Kang, S. P., Ebbinghaus, S. & 2 othersAnderson, K. M. & Gangadhar, T. C., Oct 15 2018, In : Clinical Cancer Research. 24, 20, p. 4960-4967 8 p.

Research output: Contribution to journalArticle

Melanoma
Survival
Neoplasms
pembrolizumab
Ligands
60 Citations (Scopus)

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., Sznol, M., Hainsworth, J., Rathmell, W. K., Stadler, W. M., Hutson, T., Gore, M. E., Ravaud, A., Bracarda, S., Suárez, C., Danielli, R. & 12 othersGruenwald, V., Choueiri, T. K., Nickles, D., Jhunjhunwala, S., Piault-Louis, E., Thobhani, A., Qiu, J., Chen, D. S., Hegde, P. S., Schiff, C., Fine, G. D. & Powles, T., Jun 1 2018, In : Nature Medicine. 24, 6, p. 749-757 9 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Disease-Free Survival
Cells
Confidence Intervals